DE60218153D1 - Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges - Google Patents

Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges

Info

Publication number
DE60218153D1
DE60218153D1 DE60218153T DE60218153T DE60218153D1 DE 60218153 D1 DE60218153 D1 DE 60218153D1 DE 60218153 T DE60218153 T DE 60218153T DE 60218153 T DE60218153 T DE 60218153T DE 60218153 D1 DE60218153 D1 DE 60218153D1
Authority
DE
Germany
Prior art keywords
treatment
proteasome inhibitors
dry eyes
disorders
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60218153T
Other languages
English (en)
Other versions
DE60218153T2 (de
Inventor
G Klimko
R Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE60218153D1 publication Critical patent/DE60218153D1/de
Application granted granted Critical
Publication of DE60218153T2 publication Critical patent/DE60218153T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
DE60218153T 2001-05-21 2002-05-17 Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges Expired - Lifetime DE60218153T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29272201P 2001-05-21 2001-05-21
US292722P 2001-05-21
PCT/US2002/015775 WO2002094311A1 (en) 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders

Publications (2)

Publication Number Publication Date
DE60218153D1 true DE60218153D1 (de) 2007-03-29
DE60218153T2 DE60218153T2 (de) 2007-06-28

Family

ID=23125916

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218153T Expired - Lifetime DE60218153T2 (de) 2001-05-21 2002-05-17 Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges

Country Status (17)

Country Link
US (1) US6740674B2 (de)
EP (1) EP1392355B1 (de)
JP (1) JP2004530699A (de)
CN (1) CN1509183A (de)
AT (1) ATE353667T1 (de)
AU (1) AU2002308760B2 (de)
BR (1) BR0209883A (de)
CA (1) CA2447909C (de)
CY (1) CY1107531T1 (de)
DE (1) DE60218153T2 (de)
DK (1) DK1392355T3 (de)
ES (1) ES2278049T3 (de)
MX (1) MXPA03010634A (de)
PL (1) PL367287A1 (de)
PT (1) PT1392355E (de)
WO (1) WO2002094311A1 (de)
ZA (1) ZA200308768B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
MX2012011604A (es) 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN103893742B (zh) * 2014-03-03 2016-01-20 中山大学中山眼科中心 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ES2084722T3 (es) 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
ATE185697T1 (de) 1992-04-21 1999-11-15 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
IL131410A0 (en) 1997-02-15 2001-01-28 Proscript Inc Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
BR9906772A (pt) 1998-07-14 2000-09-26 Alcon Lab Inc Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
EP1166781A4 (de) 1999-01-20 2002-08-21 Kyowa Hakko Kogyo Kk Proteasomhemmer
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
CN100357267C (zh) 1999-04-27 2007-12-26 诺瓦提斯公司 2,4－二氨基－3－羟基羧酸衍生物在制备作为蛋白酶体抑制剂的药物中的用途

Also Published As

Publication number Publication date
CN1509183A (zh) 2004-06-30
ATE353667T1 (de) 2007-03-15
JP2004530699A (ja) 2004-10-07
CA2447909C (en) 2011-04-05
CY1107531T1 (el) 2013-03-13
US6740674B2 (en) 2004-05-25
DK1392355T3 (da) 2007-04-30
MXPA03010634A (es) 2004-03-09
PT1392355E (pt) 2007-03-30
ES2278049T3 (es) 2007-08-01
AU2002308760B2 (en) 2006-05-11
CA2447909A1 (en) 2002-11-28
EP1392355B1 (de) 2007-02-14
PL367287A1 (en) 2005-02-21
EP1392355A1 (de) 2004-03-03
DE60218153T2 (de) 2007-06-28
ZA200308768B (en) 2005-01-26
US20030008910A1 (en) 2003-01-09
BR0209883A (pt) 2004-06-08
WO2002094311A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ATE254461T1 (de) Behandlung von augenschmerzen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE50312145D1 (de) Vorrichtung zur behandlung von frakturen des femur
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE419851T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
ATE264101T1 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE347883T1 (de) Verwendung von n-(2-aryl-propionyl)-sulfonamiden zur behandlung von rückenmarkverletzungen
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
ATE333273T1 (de) Verwendung von nf-kappa.b inhibitoren zur behandlung von augentrockenheit
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE286390T1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
DE60012163D1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition